SVB Leerink analyst Danielle Antalffy raised her price target for Insulet to $185 from $160 after talking with management and coming away "very bullish" on both the insulin pump market and the company's competitive position within it, supported by a highly differentiated form factor, a highly differentiated pay-as-you- go business model, and a compelling pipeline on the "Horizon." Further, the analyst argues that Insulet remains one of the cleanest execution stories in SMID-Cap MedTech, as it is well-positioned to grow the Type 1 market and only just now beginning to unlock the 2M-plus insulin-dependent Type 2 market. Antalffy reiterates an Outperform rating on the shares.